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malignanciesAbstract Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) by the closed technique provide a promising therapeutic option for highly
selected patients with peritoneal carcinomatosis. CRS with HIPEC is a long and complex procedure
with signiﬁcant blood and ﬂuid loss, hemodynamic, hematological, and metabolic alterations in the
perioperative period, with resultant morbidity and mortality. This work was done to evaluate our
early experience in anesthesia and early postoperative care for these cases.
Patients and methods: This retrospective study was done on 13 patients for CRS and HIPEC, with
intraoperative and early postoperative recording and evaluation of the ﬂuid and blood losses and
replacement, changes in hemodynamic, metabolic, and respiratory parameters and any complica-
tions happened.
Results: Our data demonstrated high ﬂuid and blood losses during CRS. During HIPEC,
raised body temperature, increased central venous pressure and airway pressure, increased arterial
partial carbon dioxide tension (PaCO2), decreased ratio of arterial oxygen partial pressure/fractional
inspired oxygen (PaO2/FiO2), and increased serum lactate were recorded. These were associated with
hemodynamic, metabolic, and respiratory acidosis. The patients were continuing resuscitation and
correction of any derangements in intensive care unit.
Conclusion: CRS and HIPEC have become standard treatment for certain peritoneal surface
malignancies. This extended surgery is considered a challenge for the anesthetist. It is associated with
312 J.M. Kamal et al.relevant ﬂuid, blood, and protein losses, together with hemodynamic, respiratory, and metabolic
derangements. However, these derangements are short lived and could be controlled by continuous
monitoring and rapid intervention.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
Open access under CC BY-NC-ND license.1. Introduction
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) provide a promising therapeutic op-
tion for highly selected patients with peritoneal carcinomatosis
arising from different malignancies such as colorectal cancer,
gastric cancer, ovarian cancer, or peritoneal mesothelioma with
improvement of both patient survival and quality of life [1].
In this technique, the chemotherapeutic agent is typically
perfused within the abdominal cavity for 90 min at a tempera-
ture of 42 C, achieving high peritoneal concentrations with
limited systemic absorption [2].
CRS with HIPEC is a long and complex procedure with sig-
niﬁcant blood and ﬂuid loss during debulking, hemodynamic,
hematological, and metabolic alterations before and during the
HIPEC phase, and even in the early postoperative period, with
resultant signiﬁcant morbidity and mortality [3–5]. For the
safety of the patient, both the surgeon and the anesthetist
should understand these profound effects with this procedure
and how to deal with, to achieve better outcome.
The aim of this work is to study, understand, and evaluate
the intraoperative and early postoperative effects of CRS and
HIPEC on hemodynamic, hematological, metabolic, and respi-
ratory functions and perioperative ﬂuid and blood losses and
replacement. Also, assessment of the perioperative treatment
related morbidity and mortality to improve the intraoperative
and postoperative outcome of this treatment strategy.2. Methods
This retrospective study was done on patients with CRS and
HIPEC with a standard closed technique, done in the Depart-
ment of Surgery of the National Cancer Institute, Cairo Uni-
versity between March 2010 and January 2011. After the
approval of the local ethics committee of National Cancer
Institute, Cairo University, data were collected from anesthe-
sia and ICU sheets, and the study was done on 13 patients,
ASA physical status class I and II patients.
Two hours prior to induction of general anesthesia Raniti-
dine 150 mg was given, and then, antibiotic and Ondansetron
4 mg were given intravenously before induction. Another dose
of antibiotic was given with starting HIPEC phase.
Standardmonitoring of the patients with electrocardiogram,
capnography, and pulse oximetry was started. Anesthesia was
induced intravenously, after volume preload, with fentanyl 3–
5 lg kg1 and Propofol 2–3 mg kg1 given intravenously, and
intubation was facilitated with Atracurium 0.5 mg kg1. Venti-
lation was controlled; anesthesia was maintained with Sevoﬂu-
rane in oxygen, maintenance shot doses of relaxant and
supplemented with either intravenousMorphine 10 mg and fen-
tanyl 50–100 lg shots, or epiduralmarcaine 0.25%10–15 ml bo-
lus and 5 ml shot doses throughout the surgery. Large-bored
intravenous cannulas, an arterial cannula, central venous line,
and a urinary catheter were then applied.Continuous monitoring of invasive arterial blood pressure,
central venous pressure, core temperature by an esophageal
probe placed at the middle third of the esophagus, airway pres-
sure, and urinary output were started.
Observation and recording of changes in pulse rate, mean
arterial blood pressure, airway pressure, central venous pres-
sure (CVP), urine output, ascetic ﬂuid drainage, and blood loss
were started from the start of surgery. Signs of volume loss
were treated by intravenous (i.v.) crystalloids, colloids, blood
and fresh frozen plasma, or vasoactive drugs to keep mean
arterial pressure above 60 mmHg and within 20% of baseline
values.
The heated chemotherapy was perfused with a closed abdo-
men technique, taking from 60 to 90 min., the abdomen is
closed at the skin level and the Tenckhoff catheter, and suction
drains and temperature probes exit through the abdominal
wound. A roller pump forces the heated chemotherapy solu-
tion into the abdomen through the inﬂow catheter and pushes
it out through the outﬂow catheter. The chemotherapeutic was
chosen according to the type of tumor, which was Cisplatin for
ovarian carcinoma and Mitomycin for colorectal carcinoma
and pseudomyxoma peritonei. A heat exchanger which keeps
the ﬂuid being infused at 44–46 C, so that the intraperitoneal
ﬂuid temperature was maintained at 42–43 C. Following the
heated infusion, the surgeon performed the anastomoses and
reconstructive procedures.
Arterial blood samples were collected for full blood count,
blood gas analysis, electrolytes, and glucose during resection to
assess the patient condition and correct any abnormalities
15 min before the HIPEC procedure. Measurements done be-
fore HIPEC included the following: heart rate, mean arterial
pressure, central venous pressure end tidal CO2, airway pres-
sure, urinary output, core temperature, and arterial blood
gases. Other recordings were done 30 min after starting chemo-
therapy infusion and 15 min after the end of the procedure.
During the HIPEC procedure, the urinary output was re-
corded every 15 min, intravenous ﬂuids increased to about
1000–1500 ml/h, together with or without an IV dose of dopa-
mine (3 lg/kg/min) aiming to keep urinary output at more
than 100 ml every 15 min. Any intraoperative complication
was recorded.
With good replacement, general surgical condition and
hemostasis, and accepted blood gases and vital signs, extuba-
tion was done in the theater, or the patient was shifted and
intubated to continue mechanical ventilation in the intensive
care unit (ICU) till correction and stabilization of vital signs.
All patients were shifted to ICU and monitoring is continued
with recording of wound and nasogastric tube drainage.
Complete blood investigations were done including complete
blood picture, liver functions, renal functions, electrolytes,
coagulation proﬁle, arterial blood gases analysis, and chest
X-ray upon patient arrival. Correction of any derangements,
replacement, inotropic support, and ventilatory support started
according to the patient condition, urine output, and amount
of drained ﬂuids from the wound and from nasogastric tube
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molecular weight heparin, and prophylactic antiulcer measures
started in all patients if no contraindication existed.
Quantitative data were expressed as range and/or
mean ± standard deviation (SD). Paired Student’s t-tests or
two-way analysis of variance (ANOVA) test was used for var-
iable differences in groups, and Bonferroni correction tests
were used for correction of multiple comparisons. P va-
lue < 0.05 was considered statistically signiﬁcant and P va-
lue > 0.05 was considered nonsigniﬁcant.3. Results
From March 2011 to January 2012, combined CRS and HI-
PEC were done for 13 patients for the management of perito-
neal carcinomatosis. Patients’ characteristics, primary
diagnosis, and operation time are summarized in Table 1.
3.1. Intraoperative data
The crystalloid and colloid intake, blood and fresh frozen plas-
ma transfused, estimated blood loss, and urine output are re-
corded for all patients during surgery in Table 2. Also, a
number of patients who received potassium infusion, vasoac-
tive drugs to manage hypotension, epidural analgesia, and
dopamine infusion were recorded.
The changes recorded before, during, and after HIPEC pro-
cedure in temperature, hemodynamic changes, acid–base, oxy-
genation, gas exchange, airway pressure, and CVP in 12
patients (one patient not included) are illustrated in Fig. 1A–I.
There was a progressive nonsigniﬁcant decrease in pH be-
fore, during and after HIPEC than baseline, and a signiﬁcant
decrease in bicarbonate levels before, during, and after HIPEC
(18.3 ± 2.3, 17.5 ± 2.1, and 16.3 ± 1.9 mmol l1, respectively)
than the baseline measurements (25.7 ± 1.1 mmol l1) was re-
corded. Serum lactate levels, measured after HIPEC, were sig-
niﬁcantly increased than before HIPEC (4.7 ± 2.2 mmol l1
and 1.7 ± 1.2 mmol l1, respectively). The core temperature
was signiﬁcantly decreased after the cytoreductive surgery
and before HIPEC than the baseline (33.5 ± 1.7 C and
36.5 ± 0.6 C, respectively) then signiﬁcantly increased during
HIPEC (38.2 ± 1.1 C) and persisted after completion
(38 ± 0.8 C) than before this phase.
PaCO2 was increased signiﬁcantly during the HIPEC than
before (from a mean of 32.7 ± 3.5 to 39.4 ± 2.5 mmHg) thenTable 1 Characteristics of 13 patients undergoing CRS and HIPEC
Sex Male
Female (number)
Age (years)
Weight (kg)
Height (c)
ASA 1
ASAII (number)
Primary diagnosis (number)
Total time of operation (h)
Time of surgery (h)
‘‘American Society of Anesthesiologists Grade’’ (ASA).decreased again after HIPEC to 37.8 ± 2.2 mmHg, which is
still signiﬁcantly increased than before HIPEC. Tissue oxygen-
ation was also affected, with signiﬁcant decrease in the PaO2/
FiO2 (from 361 ± 44.8 before to 196 ± 29.1 during HIPEC),
to increase again after completion of HIPEC to 240 ± 34.2.
With abdominal closure during HIPEC, there is a concom-
itant signiﬁcant increase in airway pressure than before closure
(26.3 ± 3.6 vs 17.5 ± 2.1 cm H2O) and central venous pres-
sure (12.25 ± 2.2 vs 8.5 ± 1.2 cm H2O). Then, after comple-
tion of HIPEC and abdominal opening, the airway pressure
and CVP decreased signiﬁcantly than during the HIPEC
(18.6 ± 2.3 cm H2O and 9.5 ± 1.4 cm H2O, respectively) but
without signiﬁcant changes from baseline and before HIPEC.
Regarding hemodynamic changes, there was signiﬁcant
increase in heart rate during CRS before HIPEC than the
baseline readings (77.4 ± 14.2 vs 70.4 ± 8.1 beat/min) and
also signiﬁcantly increased more during HIPEC (94 ± 12
beat/min), which decreased after HIPEC (85.6 ± 11.5 bpm)
but still signiﬁcantly increased than baseline and before HI-
PEC. Mean arterial pressure decreased signiﬁcantly before
|HIPEC than baseline (84.3 ± 9.2 vs 89.1 ± 11.1 mmHg)
and decreased signiﬁcantly more during chemotherapeutic
infusion (75 ± 9.3 mmHg) then signiﬁcantly increased again
after completion of the procedure than during HIPEC
(81.2 ± 11 mmHg), but still signiﬁcantly less than baseline.
No intraoperative patient mortality and intraoperative
complications are listed in Table 3. The HIPEC phase was
done to all patients except for one case.
3.2. Postoperative data
All the patients were shifted to the ICU; seven of them were
intubated, and ﬁve patients were on inotropic support. The
early postoperative patients’ data in ICU, in day 0 (the period
from end of the operation until start of ﬁrst postoperative day),
which is 8.2 ± 2.5 h, day 1, and day 2 are listed in Table 4.
Compared to baseline records, there was persistent signiﬁ-
cant decrease in Hb in day 0 than baseline (11.5 dl1). Also,
there was persistent signiﬁcant decreased bicarbonate, in-
creased serum lactates, with decreased pH in day 0 than base-
line, and was not signiﬁcantly different in the following days.
Signiﬁcant increased INR (international normalized ratio) in
days 0 and 1 than baseline (1.1 ± 0.12) was normalized in
3 days except with patients with impairment of liver enzymes.
There was signiﬁcant decrease in mean albumin level) in days
0, 1, and 2 compared to baseline records (3.5 ± 0.61 g/dl).. Data are expressed as number and mean ± SD.
6
7
50.2 ± 7.5
67 ± 8.6
156 ± 7.8
9
4
Ovarian cancer: 4
Pseudomyxoma Peritonii: 4
Peritoneal, colorectal carcinomatosis: 5
8.45 ± 2.7
7.30 ± 1.8
Table 2 Intraoperative ﬂuids and blood products, urine output, potassium, dopamine and inotrope infusion, and epidural analgesia
of 13 patients.
Mean ± SD Range Number of patients (total: 13)
Total crystalloid (ml) 7571.4 ± 4004 5000–15,000 13
Total colloid (ml) 1714 ± 1219 500–4000 13
Red blood cells (units) 5.7 ± 3.3 2–10 13
Fresh frozen plasma (units) 6 ± 3.7 2–10 12
Estimated blood loss (ml) 3400 ± 1622 1300–5000 13
Albumin 25% (ml) 157.3 ± 53 100–200 7
Total urine output (ml) 3880 ± 402 3200–4500 13
Urine output during HIPEC (ml) 1283 ± 248 1000–1500 13
Potassium infusion 20 meq/h 8
Dopamine infusion (lg/kg) 3 lg/kg/min 9
Inotrope infusion (adrenaline or noradrenaline) 5
Epidural analgesia (ml/h) 5 ± 2.3 ml/h 5–8 ml/h 5
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dynamic complications, chest related complications, liver
impairment, kidney impairment, and the number of patients
died in ICU are listed in Table 5.
4. Discussion
This study presents our early experience with CRS and HI-
PEC. It includes anesthetic considerations, intraoperative
events and derangements with their management, and the early
postoperative course in the ICU with reference to the morbid-
ity and mortality. Closed technique was used to achieve and
maintain hyperthermia with minimal heat loss and with mini-
mal contact or aerosolized exposure of the operating room
staff to the chemotherapy. Tumoricidal activity is achieved
at 41–43 C; that in-ﬂow temperature usually exceeds 45 C
[1,6].
CRS and HIPEC are complex lengthy procedures involving
exploratory laparotomy, extensive peritoneal and multivisceral
resection, abdominal closure, then perfusion of high-dose of
intraperitoneal hyperthermic chemotherapy, and performing
a number of anastomoses. This complex surgical procedure
was associated with signiﬁcant ﬂuid loss, ﬂuid shift, blood loss,
and protein loss with the hyperthermic chemotherapy [3,4].
In our study, infusions with crystalloids, colloids, fresh fro-
zen plasma, albumin, and blood were guided by continuous
monitoring of pulse, blood pressure, central venous pressure,
serum electrolytes, hemoglobin, and urine output. The infu-
sion rate was high during resection stage, to restore normovol-
emia, cardiovascular system stability, and correction of
electrolytes before HIPEC, and was high during HIPEC to
maintain good perfusion pressure, to maintain good urine out-
put and to compensate for vasodilatation caused by the heated
chemotherapy and the increased intraabdominal pressure.
Adequate urine output (0.5–1 ml/kg/h) and CVP (6–8 mm
H2O) were our aim, which sometimes need IV Furosemide to
avoid tissue edema that was crucial for safe anastomoses (usu-
ally requested by the surgeon). Red blood cell transfusion was
necessary to all patients intraoperatively, and also, fresh frozen
plasma was transfused for clinical evident bleeding to compen-
sate for coagulation factor defect.
Nguyen and Wolfe in 2005 reported that adequate ﬂuid
therapy and blood replacement play a major role in the main-tenance of adequate systemic and regional perfusion and pre-
vent systemic hemodynamic disorders, that is, a critical
factor when the blood volume is low [7]. Other studies reported
that blood loss was due to surgery and disturbance of coagu-
lation with an increased INR and fall in AT III values, as well
as prolonged aPTT and a reduced number of platelets. Addi-
tionally, coagulation could be abnormal due to lower values
of coagulation factors not measured with standard tests, such
as factor XIII [3,7,8]. Signiﬁcant risk factors necessitating
intraoperative blood transfusion in CRS were studied by other
authors; the most important were operative length more than
9 h, preoperative INR more than 1.2, preoperative hemoglobin
less than 125 g/l, and peritoneal cancer index C 16 [9].
Esophageal temperature was continuously measured
throughout the study. Although hypothermia during CRS
was controlled by forced air warming with blankets and
warmed ﬂuid infusions, all the patients were hypothermic be-
fore the HIPEC. This can be explained by the large amount
and rapid rate of infusions together with the large surface area
exposed for long time. Then, the temperature started to in-
crease with infusion of the hyperthermic solution during and
after ﬁnishing the HIPEC procedure. The body temperature
rise was controlled by stopping of the heating measures used
during surgery, cold and rapid infusions, and the cooling mea-
sures of the skin. This agrees with Kanakoudis in 1996, who
found the core body temperature during the hyperthermic per-
fusion period increased signiﬁcantly but remained within clin-
ically acceptable values [10]. In other study during
chemotherapeutic perfusion, there were signiﬁcant increases
in mean temperature, and despite the intensive cooling mea-
sures, 18% of patients had an increase in core temperature
greater than 39 C [4].
Hemodynamically, our patients had signiﬁcant increase in
heart rate and decrease in mean arterial pressure with CRS;
this can be due to blood loss, ﬂuid loss, and hypothermia.
Tachycardia and hypotension increased more with abdominal
closure and infusion of the heated chemotherapy due to rise of
body temperature and decreased systemic vascular resistance.
As it was found that, during HIPEC, the increased body tem-
perature results in corresponding increase in metabolic rate,
the patients developed hyperdynamic circulation with increase
in heart rate and in end tidal carbon dioxide values, with met-
abolic acidosis and elevated lactate levels [3,4,10].
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Figure 1 Intraoperative hemodynamic and metabolic changes, airway pressure, and central venous pressure (CVP) of 12 patients before,
during, and after HIPEC compared to baseline.
Table 3 Intraoperative complications of 13 patients.
Intraoperative complication Number of
patients (total: 13)
Blood loss (>10% of blood volume) 13
Hypotension (>20% decrease
in mean arterial pressure)
9
Hypokalemia < 3 meq/L 6
Metabolic acidosis 13
Diaphragmatic tear 4
Temperature > 38.5 C 2
Pulmonary edema 1
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for hemodynamic support in four patients during HIPEC and
continued postoperatively then weaned in ICU thereafter.
These hemodynamic and cardiac function changes during HI-
PEC were also reported in other studies with increased heart
rate, decreased arterial pressure, increased cardiac output,
and decreased systemic vascular resistance. These effects were
explained to be due to the reduction in the venous return by
narrowing of the vena cava associated with a reduction in
the abdominal blood volume and an increase in splanchnic
vascular resistance [3,4,8,11–13].
The development of combined metabolic and respiratory
acidosis in all patients of the study was recorded, which
Table 4 Patients’ progress in the early postoperative period in ICU.
Day 0 Day 1 Day 2
Hemoglobin (g dl1) 7.8 ± 1.3* 10.2 ± 1.2 10.5 ± 1.8
Platelet count (109 l1) 148.7 ± 67 162.2 ± 77 165 ± 58.6
White blood cells 8.6 ± 4.8 12.6 ± 6.8 9.5 ± 2.8
Temperature (C) 37.3 ± 0.4 37.7 ± 0.6 37.9 ± 0.6
INR 1.8 ± 0.53* 1.5 ± 0.45* 1.3 ± 0.68
Fibrinogen (g/L) 236 ± 220 539 ± 450 654 ± 622
pH 7.28 ± 0.1* 7.38 ± 0.06 7.39 ± 0.11
HCO3 (mmol l
1) 18.3 ± 3.8* 26 ± 3.5 26.5 ± 1.3
Lactate (mmol l1) 5.2 ± 2.5* 3.2 ± 1.3 2.5 ± 1.1
Albumin (g/dl) 2.1 ± 0.7* 2.4 ± 0.5* 2.8 ± 0.8*
IV ﬂuids (ml/h) 192 ± 45 167 ± 44 150 ± 32
Drains (ml/day) 483 ± 220 688 ± 223 520 ± 170
Nasogastric tube drainage (ml/day) 167 ± 172 300 ± 76 240 ± 66
Urine output (ml/day) 857 ± 254 1820 ± 455 1552 ± 370
* p< 0.05 compared to baseline value.
Table 5 Early postoperative complication.
Type of complication Number of patients (total 13)
Inotropic support 4
Tachycardia 11
Arrhythmia 1
Heart failure 1
Fever 12
Reintubation and ventilation 2
Pneumonia 3
Pulmonary embolism 1
Pleural eﬀusion 3
Renal impairment 0
Liver impairment 7
intestinal leak 1
Platelet dysfunction 0
Death 2
316 J.M. Kamal et al.appears to be mainly metabolic. Metabolic acidosis in most of
the cases started before the start of HIPEC procedure and in-
creased more during and after the hyperthermic perfusion with
a signiﬁcant decrease in bicarbonate and increased lactate lev-
els. This was explained by hypothermia, hypotension, ﬂuid
losses, blood loss, and increased intraabdominal pressure.
No bicarbonate infusion was given except in one case, after
pH reached 7.14 during hyperthermic perfusion. Also, gas ex-
change was impaired with signiﬁcant increase in PaCO2 due to
the hypermetabolic state. This was observed by other centers,
with development of both metabolic and respiratory acidosis
with persistent mild metabolic acidosis after completion of
the procedure [3–5,14].
In this study, we observed signiﬁcant increases in central ve-
nous pressures, airway pressure, PaCO2, and a signiﬁcant de-
crease in PaO2/FiO2 during and after HIPEC. It was also
found in other studies using closed abdomen technique, an in-
crease in intraabdominal pressure, together with shift of the
diaphragm resulting in an increase in airway pressure and a
reduction in the functional residual capacity. These changes
lead to rise in the central venous pressure, decreased lung vol-
ume, a decrease in the oxygenation ratio, together with hyper-
dynamic circulation during HIPEC characterized by increasein end tidal carbon dioxide values and increased systemic oxy-
gen demand [3,10,15–17]. Shime et al. found an increased oxy-
gen consumption and a slight rise in oxygen extraction due to
hyperthermic metabolic conditions during HIPEC [11].
All the patients in the study received potent antiemetic pre-
operatively to control the emetic effect of chemotherapy. Intra-
peritoneal chemotherapy complications include those linked to
the drug administered; Cisplatin administration results in nau-
sea, vomiting, and renal toxicity which was avoided by effec-
tive antiemetic drugs and suitable i.v. hyperhydration
considering the systemic exposure to the agent after intraperi-
toneal application [18,19].
With the start of chemotherapeutic infusion, increased ﬂuid
infusion and dopamine infusion 3 lg/kg started in 9 patients,
with a maintained urine output during HIPEC procedure
reaching 1000–1500 ml/h. During HIPEC, adequate urine out-
put is mandatory and is considered a reﬂection of good kidney
perfusion, especially during the periods of increased intraab-
dominal pressure, heated chemotherapeutic infusion with its
concomitant peripheral vasodilatation, and as a protective
from renal toxicity [3,18].
Intraoperative pain was controlled by intravenous fentanyl
and morphine or by combined epidural infusion of local anes-
thetic and fentanyl, and it was found that pain control by any
of the two ways was not related to postoperative ventilation.
Other studies have reported that patients receiving epidural
analgesia required less postoperative mechanical ventilation,
while others postulated that cytoreductive surgery and HIPEC
can be achieved with or without epidural analgesia [3,4].
There was no intraoperative mortality, and only one patient
suffered from severe hypotension due to severe bleeding, which
was not controlled by vasoactive drugs, and the HIPEC proce-
dure could not be done. The intraoperative complications of
HIPEC which was recorded in all patients were bleeding,
extensive ﬂuid loss, and metabolic acidosis. Five patients
developed hypotension necessitating inotropic support, and
four patients had diaphragmatic tear with intraoperative chest
tube insertion. One patient had pulmonary edema with de-
crease in oxygen saturation during surgical resection which
may be due to rapid infusion and low albumin level that was
controlled by frusemide and positive pressure ventilation and
later albumin infusion.
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All the patients in the study were shifted to ICU for stabiliza-
tion of hemodynamic and ventilation, correction of acid–base,
and assessment of organ functions. This was reported in other
studies that postoperatively, most patients should be trans-
ferred to the ICU, as postoperative ﬂuid loss during the ﬁrst
72 h following surgery is still very high. In other stud-
ies, patients were transferred either to the post-anesthesia care
unit (PACU) or to intensive care unit (ICU) depending on
their overall status [3–5].
The average length of stay in ICU was 4.4 days (range of 2–
10 days). Seven patients admitted and intubated to continue
mechanical ventilation; four of them because of intraoperative
diaphragmatic tear, and the rest with unstabilized hemody-
namics or ventilation. All the patients were extubated in the
early morning of the ﬁrst day except two patients were extubat-
ed on the second day after stabilization of the general condi-
tion and correction of gas exchange and oxygenation.
On day 0, blood pressure was stable except for four patients
who were controlled by intravenous inotropic drug infusions,
blood transfusion, and ﬂuid intake; and weaning was complete
on the ﬁrst day. Tachycardia was present in most of the pa-
tients (n= 10), which was stabilized on the ﬁrst day by stabil-
ization of the hemodynamic and metabolic parameters, ﬂuid
intake and blood transfusion, pain control, and control of in-
creased temperature. One patient developed atrial ﬁbrillation,
another one developed left sided heart failure, and both were
managed according to their condition.
Liberal intravenous ﬂuid intake, crystalloid and colloid,
was guided by hemodynamic changes, CVP, serum electro-
lytes, urine output, and amount of ﬂuid losses from drains
and nasogastric tube. Blood transfusion was mostly given on
day 0 (n= 8) together with fresh frozen plasma guided by
the drains, hemoglobin percent and hematocrit value, and
coagulation proﬁle. Also, there were signiﬁcantly decreased
albumin levels, which started to fall during surgery and re-
mained low postoperatively. Albumin was given to all patients
to keep serum albumin above 3.0 g/dl and to compensate for
ﬂuid losses and excess abdominal ﬂuid rich protein drained.
Postoperative ﬂuid losses via the drains and the nasogas-
tric tube drainage were very high in day 0 and day 1 in
ICU and then decreased gradually with the next days. In
other studies, the daily amount of ﬂuid collected by drains
decreased progressively from the 1st to the 7th postoperative
day, and the daily ﬂuid output of the nasogastric tube was
close to 1000 ml/24 h until day 6 [20]. Schmidit et al. in
2008 reported that ﬂuid loss during the ﬁrst postoperative
72 h averaged 5.7 l/day, and 42% of ﬂuid losses came from
abdominal drains [3].
Temperature increased in all patients on the ﬁrst and second
days (mean of 37.7 and 37.9) and started to normalize after
that except for 2 patients, which continued with fever with start-
ing pneumonia. In addition, the ﬁbrinogen level was elevated
from the ﬁrst postoperative day and continued elevation in the
ICUstay time. Baratti et al. (2010) reported that the temperature
was close to 38 during the ﬁrst 10 postoperative days, in the ab-
sence of sepsis. Together with the high temperature, a gradual
and marked increase in the ﬁbrinogen level with marked diges-
tive hypersecretion, which were considered the manifestations
of the high-inﬂammatory syndrome following HIPEC [3,20].All the patients were admitted to ICU with decreased bicar-
bonate level, high serum lactate level, and metabolic acidosis,
which were normalized by day 1 due to stabilization of the
hemodynamics, normalization of temperature, and ﬂuid and
blood replacement.
Continuous monitoring for our study patients for any chest
complication was done; good prophylactic antibiotic coverage
was given; and chest physiotherapy was started from day 1
under supervision of physiotherapist with good pain control
to prevent lung collapse. Four patients were admitted with
chest tube drainage after intraoperative diaphragmatic tear
and two patients developed minimal pleural effusion not neces-
sitating drainage. It was explained by Baratti et al. that the
inﬂammatory reactions could be responsible for production
of postoperative exudative pleural effusion [20]. Three patients
developed pneumonia with resultant hypoxia and fever; two of
them were intubated and ventilated. Another patient had
ventilation/perfusion scan done with a high probability of
pulmonary infarction. A study was done to determine the inci-
dence and severity of thoracic reactions in patients undergoing
intraperitoneal heated chemotherapy. Thoracic complications
occurred in 86% of the study patients, including atelectasis,
pleural effusions, pulmonary edema, pneumonia, and pneumo-
thorax [21].
Different cytostatic agents used for HIPEC can lead to sys-
temic toxicity as bone marrow depression in the form of leuco-
penia, anemia, thrombocytopenia, heart, liver or renal toxicity,
and other side effects [4,22].
In our study, the average hemoglobin percent on admission
to ICU ranged 6.9–11.2 g dl1, which was corrected if needed
by blood transfusion to be maintained above 10 g dl1 in the
next days. Leukocytic count and platelet count were within
normal average limits, without great changes within the pa-
tients’ stay in ICU. INR was signiﬁcantly higher than baseline
on day 0 due to intraoperative dilution of coagulation factors,
which necessitate fresh frozen plasma transfusion in patients
with excess uncontrolled ooze. It is normalized gradually with-
in 3 days, except in three cases, that took longer time because
of association of liver impairment and high liver enzymes. Yan
and his colleagues reported that a low hemoglobin level of
6.5–7.9 g dl1 in 26% upon ICU admission of their patients.
This was explained as hemodilution, since patients are given
a large volume of intravenous ﬂuid intraoperatively. Also,
there were signiﬁcant decreases in prothrombin time and
increase in INR that was normalized within 5 days in 78%
of their patients [23].
There were good urine output, no signs of renal failure, or
signiﬁcant changes in kidney functions were observed in any
patient in the study. Raft et al. retrospectively analyzed the
perioperative care of 20 patients who underwent HIPEC, and
there was no renal failure or impact on blood cells counts
for 7 days postoperatively [14].
There were more than threefold increases in liver enzymes,
elevated bilirubin level, increase in INR, and decrease in pro-
thrombin concentration in seven patients, maximum on the
ﬁrst and second day in ICU then gradually normalized in the
next days. Hepatic tests in other studies showed early but mod-
erate cytolysis without cholestasis. Transaminases increased
twofold to threefold during the ﬁrst 4 postoperative days
which was explained to be due to extensive electro coagulation
of the liver capsule [20].
318 J.M. Kamal et al.Pain was controlled either by continuous epidural infusion
of marcaine 0.125% and fentanyl, or by intravenous shots of
morphine.
Two patients died in ICU; one of them due to liver cell fail-
ure and the other due to intestinal perforation and leak.
6. Conclusion
Cytoreductive surgery with hyperthermic intraperitoneal che-
motherapy has become standard treatment for selected pa-
tients with certain peritoneal surface malignancies. This
extended surgery is considered a challenge for the anesthetist.
It is associated with relevant ﬂuid, blood, and protein losses,
together with hemodynamic, respiratory, and metabolic
derangements. However, these derangements are short lived,
easy to control, and not likely to contribute to morbidity
and mortality. Continuous monitoring intraoperatively and
postoperatively with rapid interaction with anticipated events
is essential. This is together with good understanding of both
the surgeon and the anesthetist about these effects and a strong
and rapid interaction between them.
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